OBJECTIVE: Sickle cell anemia (SCA) causes chronic inflammation and multiorgan damage. Less understood are the arterial complications, most evident by increased strokes among children. Proteolytic mechanisms, biomechanical consequences, and pharmaceutical inhibitory strategies were studied in a mouse model to provide a platform for mechanistic and intervention studies of large artery damage due to sickle cell disease. Approach and Results: Townes humanized transgenic mouse model of SCA was used to test the hypothesis that elastic lamina and structural damage in carotid arteries increased with age and was accelerated in mice homozygous for SCA (sickle cell anemia homozygous genotype [SS]) due to inflammatory signaling pathways activating proteolytic enzymes. Elastic lamina fragmentation observed by 1 month in SS mice compared with heterozygous littermate controls (sickle cell trait heterozygous genotype [AS]). Positive immunostaining for cathepsin K, a powerful collagenase and elastase, confirmed accelerated proteolytic activity in SS carotids. Larger cross-sectional areas were quantified by magnetic resonance angiography and increased arterial compliance in SS carotids were also measured. Inhibiting JNK (c-jun N-terminal kinase) signaling with SP600125 significantly reduced cathepsin K expression, elastin fragmentation, and carotid artery perimeters in SS mice. By 5 months of age, continued medial thinning and collagen degradation was mitigated by treatment of SS mice with JNK inhibitor. CONCLUSIONS: Arterial remodeling due to SCA is mediated by JNK signaling, cathepsin proteolytic upregulation, and degradation of elastin and collagen. Demonstration in Townes mice establishes their utility for mechanistic studies of arterial vasculopathy, related complications, and therapeutic interventions for large artery damage due to SCA.
OBJECTIVE:Sickle cell anemia (SCA) causes chronic inflammation and multiorgan damage. Less understood are the arterial complications, most evident by increased strokes among children. Proteolytic mechanisms, biomechanical consequences, and pharmaceutical inhibitory strategies were studied in a mouse model to provide a platform for mechanistic and intervention studies of large artery damage due to sickle cell disease. Approach and Results: Townes humanized transgenic mouse model of SCA was used to test the hypothesis that elastic lamina and structural damage in carotid arteries increased with age and was accelerated in mice homozygous for SCA (sickle cell anemia homozygous genotype [SS]) due to inflammatory signaling pathways activating proteolytic enzymes. Elastic lamina fragmentation observed by 1 month in SSmice compared with heterozygous littermate controls (sickle cell trait heterozygous genotype [AS]). Positive immunostaining for cathepsin K, a powerful collagenase and elastase, confirmed accelerated proteolytic activity in SS carotids. Larger cross-sectional areas were quantified by magnetic resonance angiography and increased arterial compliance in SS carotids were also measured. Inhibiting JNK (c-jun N-terminal kinase) signaling with SP600125 significantly reduced cathepsin K expression, elastin fragmentation, and carotid artery perimeters in SSmice. By 5 months of age, continued medial thinning and collagen degradation was mitigated by treatment of SSmice with JNK inhibitor. CONCLUSIONS: Arterial remodeling due to SCA is mediated by JNK signaling, cathepsin proteolytic upregulation, and degradation of elastin and collagen. Demonstration in Townes mice establishes their utility for mechanistic studies of arterial vasculopathy, related complications, and therapeutic interventions for large artery damage due to SCA.
Authors: Chan Woo Kim; Anastassia Pokutta-Paskaleva; Sandeep Kumar; Lucas H Timmins; Andrew D Morris; Dong-Won Kang; Sidd Dalal; Tatiana Chadid; Katie M Kuo; Julia Raykin; Haiyan Li; Hiromi Yanagisawa; Rudolph L Gleason; Hanjoong Jo; Luke P Brewster Journal: Circulation Date: 2017-08-04 Impact factor: 29.690
Authors: S Laurent; P Boutouyrie; R Asmar; I Gautier; B Laloux; L Guize; P Ducimetiere; A Benetos Journal: Hypertension Date: 2001-05 Impact factor: 10.190
Authors: Kristin P Guilliams; Melanie E Fields; Dustin K Ragan; Yasheng Chen; Cihat Eldeniz; Monica L Hulbert; Michael M Binkley; James N Rhodes; Joshua S Shimony; Robert C McKinstry; Katie D Vo; Hongyu An; Jin-Moo Lee; Andria L Ford Journal: Pediatr Neurol Date: 2016-12-07 Impact factor: 3.372
Authors: Antoine Gueguen; Matthieu Mahevas; Ruben Nzouakou; Hassan Hosseini; Anoosha Habibi; Dora Bachir; Pierre Brugière; François Lionnet; Jean-Antoine Ribei; Bertrand Godeau; Robert Girot; Vahid Ibrahima; David Calvet; Frédéric Galactéros; Pablo Bartolucci Journal: Am J Hematol Date: 2014-03 Impact factor: 10.047
Authors: R Adams; V McKie; F Nichols; E Carl; D L Zhang; K McKie; R Figueroa; M Litaker; W Thompson; D Hess Journal: N Engl J Med Date: 1992-02-27 Impact factor: 91.245
Authors: Christian P Rivera; Li Li; Shuangyi Cai; Nui Pei; George E McAlear; Keval Bollavaram; Oluwasanmi V Ariyo; Victor O Omojola; Hannah Song; Andrea L Alfonso; Wenchang Tan; Yunlong Huo; Manu O Platt Journal: Blood Cells Mol Dis Date: 2020-08-13 Impact factor: 3.039
Authors: Jada Selma; Hannah Song; Christian Rivera; Simone Douglas; Abhiramgopal Akella; Keval Bollavaram; Nishone Thompson; Manu O Platt; Edward A Botchwey Journal: Blood Adv Date: 2022-03-08